ERBB2 and osteoporosis: Women treated with chemotherapy and anti-HER2 therapy had a higher risk of developing osteoporosis than women treated with chemotherapy alone (HR, 1.41; 95% CI, 1.31–1.52 vs. HR, 1.3; 95% CI, 1.23–1.38, respectively).